Introduction
CD43 is a highly sialylated and O-glycosylated membrane protein with the apparent molecular weight of 100-120 kDa, and is mostly expressed in hematopoietic cells, including stem cells (1) . CD43 is involved in multiple functions, such as cell adhesion, apoptosis and migration (2) . The UN1 monoclonal antibody (mAb) was initially selected for a high reactivity against human immature thymocytes (CD3 dim ) (3) , and recognized a CD43 epitope that included the monosaccharide GalNAc-O-linked to the polypeptide chain, named UN1/CD43 antigen (4) . The UN1/CD43 antigen was expressed in human thymocytes, a subpopulation of peripheral blood CD4 + T-lymphocytes, and some leukemic T-cell lines, such as HPB-ALL, H9, and MOLT-4 (3, 5) . Moreover, the UN1/CD43 antigen was expressed at early stages of development in foetal tissues, including thymus, spleen, adrenal cortex, bronchial epithelium, and skin, and is down-regulated in ontogeny (6) . The involvement of UN1/CD43 glycoforms in oncogenesis was suggested by several findings. In fact, UN1/CD43
was detected in a variety of solid tumours, including breast, colon, gastric, and squamous cell lung carcinomas, while it was undetected in the relative normal tissues and benign lesions (6, 7) . In particular, the expression level of UN1/CD43 glycoforms in breast cancer cells correlated with the progression stage of the disease (7) . The evidence that the UN1-type CD43 membrane proteins were expressed in cancer tissues made the UN1 mAb an attractive tool for tumor detection and immunotherapy.
Several mAbs directed against surface antigens of tumor cells are currently used for cancer therapy (8) . However, mAb-based therapy has many disadvantages, such as the relatively short-lived response, the development of therapy-resistance and immune reaction overtime, and a high cost-of-production (9, 10) . As alternative to the direct use of therapeutic mAb, vaccine strategies using peptide mimics of specific epitopes to elicit a humoral and cellular immune response against tumor cells could be a more effective and economical approach (11) . In this regard, phage-displayed random peptide libraries (RPLs) have been used to select peptides that mimic natural epitopes, so called mimotopes, even in the absence of knowledge on the antigen structure (12) . Mimotopes have been used as immunogens for raising antibodies against the natural epitope, thus representing a suitable tool for immunotherapy (13) (14) (15) (16) . In particular, the mimotope-based immunization can overcome the major limitations of glycosylated antigens, including the poor immunogenicity, the inability to stimulate a long-lasting immune response, and the difficulty to synthesize and purify large quantities of glycosylated proteins for immunization (17) . To date, a few mimotopes of tumor antigens have been identified (18) (19) (20) (21) some of which raised epitope-specific antibodies for cancer vaccine (14, (22) (23) (24) (25) (26) .
In this study, we show that the passive transfer of the UN1 mAb inhibited the growth of UN1-positive lymphoblastoid T-cells upon xenograft in mice, being this inhibition mediated by antibody-dependent cell-mediated cytotoxicity. By screening a phage displayed RPL, we identified the phagotope 2/165 that expressed the peptide sequence mimicking the UN1/CD43
epitope, and we demonstrated that mice immunization with this phagotope elicited antibodies that specifically recognized UN1-positive cancer tissues. These findings support the possibility to target cancer-associated CD43 glycoforms by using immunotherapeutic strategies based on UN1 mAb and UN1 mimotopes.
Materials and Methods

Cells
Human thymic acute lymphocytic leukaemia HPB-ALL cells were obtained by the German Peripheral blood mononuclear cells were isolated from healthy donors by Ficoll-Paque gradient centrifugation (GE Healthcare Life Sciences, Piscataway, NJ, USA), as previously described (27) (28) (29) . Primary cultured NK cell populations were obtained from 10-day cocultures of PBMCs with irradiated Epstein-Barr virus-positive RPMI 8866 lymphoblastoid cell line, as previously described (30) . HPB-ALL cells and primary cultured NK cells were maintained in RPMI 1640 supplemented with 1% L-glutamine and 10% Foetal Calf Serum (Life Technologies, Carlsbad, CA, USA) (31, 32) .
RPL, antibodies and peptides
The f88-4/Cys5 phage displayed peptide library (GenBank Accession AF246454) was kindly provided by Dr. George P. Smith (University of Missouri, Columbia, USA). This library 6 contains random 15-mer peptides constrained at the N-terminus of the pVIII phage coat protein with a complexity of 5.9x10 8 primary clones (33) .
The IgG 1 isotype UN1 mAb was produced and purified by MAbTrap kit (GE Healthcare), as previously described (3) . Antibodies used as positive controls in ADCC were as follows: OKT3 mAb (eBiosciences, San Diego, CA, USA), which recognizes a CD3
epitope that is strongly expressed on HPB-ALL cells; W6/32 mAb (eBiosciences), which recognizes a non-polymorphic epitope commonly expressed in major histocompatibility complex (MHC) class I, HLA-A, B and C, on all human nucleated cells. FITC-conjugated F(ab') 2 fragment of rabbit anti-mouse immunoglobulins and IgG control were purchased from Dako (Milano, Italy). Peptides were purchased from Caslo Laboratory ApS (Lyngby, Denmark).
Cell proliferation, viability, cell-cycle and apoptosis analysis
Cell proliferation was monitored by enumerating viable cells using a hemocytometer.
Viability was determined by using Trypan blue dye exclusion. Cell cycle and apoptosis analysis were performed as previously described (34) (35) (36) .
In vivo tumour growth analysis
Six weeks old female NU/NU nude mice (BALB/c congenic Crl:NU-Foxn1 nu , Charles River Laboratories, Wilmington, MA, USA) were engrafted with HPB-ALL cells (5x10 6 ) by subcutaneous injection into the lateral flank. Then mice were randomly assigned to two treatment groups of 5 mice: one group was treated with control mouse IgG 1 (Sigma-Aldrich, Milano, Italy), the second group was treated with the UN1 mAb. The UN1 mAb or IgG 1 control (400 μg in PBS/mouse) were injected in the tail vein of mice the day after tumor cells engraftment and the inoculation was repeated at day 7 from xenograft. The tumour size was measured by calliper, three times per week, and the tumour volume was calculated by the modified ellipsoid formula π/6 x A x B 2 , where A is the longest and B the shortest perpendicular axis of an assumed ellipsoid. Mice were killed when the tumor volume reached a size of 4 cm 3 , according to the ethical guidelines. Percent specific 51 Cr release was calculated according to the following formula: percent specific release = (experimental release-spontaneous release) /(maximum release-spontaneous release) x 100. Lytic units (LU) represent the number of effector cells required to mediate 20% lysis of target cells and were calculated by using the descending phase of curves generated by 51 Cr release assay over the range of effector/target cell ratios, as previously reported (37) .
Complement-dependent cytotoxicity (CDC)
Immunological screening of phage displayed RPLs
Specific phage clones for the UN1 mAb were isolated from the library by two rounds of affinity selection, as previously described (38, 39) . To this end, the UN1 mAb (10 μg) was bacteria, and purified from plaques for a second round of affinity selection. Phage colonies were transferred according to an ordered grid on a lawn of K91BK cells on LB agar plates supplemented with 1mM IPTG. Nitrocellulose filters were layered onto these plates and incubated overnight at 37°C. Filters were blocked for 2 hours with blocking buffer (1x PBS, 5% non-fat dry milk, 0.1% NP40, 0.01% NaN 3 ) at room temperature and incubated O/N at 4°C with the UN1 mAb (1 μg/ml) in blocking buffer. Then, filters were washed with washing buffer (1x PBS, 0.1% NP40) and incubated with alkaline phosphatase-conjugated anti-mouse IgG (Fc specific) secondary antibody (Sigma-Aldrich) at the dilution of 1:5000 for 4 hours at 4°C. After extensive washing, filters were incubated in developing solution (1-Step NBT/BCIP, Pierce, Thermo Scientific, Rockford, IL, USA). Collected phage supernatants from positive clones were further analysed by ELISA.
ELISA
For assaying phage reactivity to antibodies or sera, multiwell plates (Immunoplates Maxisorp, Nunc, Milano, Italy) were coated with 10 μg/ml anti-fd bacteriophage Abs (Sigma-Aldrich) in 50 mM NaHCO 3 , pH 9.6 overnight at 4°C. After blocking with Blocking Buffer (BB) (1x PBS, 5% non-fat dry milk, 0.05% Tween 20, 0.05% NaN 3 ) for 1 hour at 37°C, the BB was discarded, and a mixture of 50 μL of BB and 50 μL of phage supernatant was added to each well. After incubation for 1 hour at 37°C, plates were washed six times with Washing Buffer (WB) (1x PBS, 0.05% Tween 20, 0.05% NaN 3 ). Then, UN1 mAb (5 μg/mL) or sera at the indicated dilution were resuspended in BB and added to the wells. After an O/N incubation at 4°C, plates were washed 6x with WB, and a 1:5000 dilution in BB of a goat anti-mouse IgG (Fc specific) alkaline phosphatase antibody (Sigma-Aldrich) was added to wells. Alkaline phosphatase was revealed by incubation with p-nitrophenyl phosphate (1 mg/ml) in 1x diethanolamine substrate buffer (Pierce Thermo Scientific). Optical density (OD) at 450 nm (OD 405 ) and 620 nm (OD 620 ) were measured by an ELISA reader (Tecan, Männedorf, Switzerland), and values were expressed as difference between OD 405 and OD 620 . Wild type phage was used as negative control (40) .
For assaying peptide reactivity to antibodies or sera, multiwell plates were coated with the indicated peptide (5 μg/mL) in 1x PBS pH 7.4. After blocking with BB, the UN1 mAb (5 μg/ml), or the indicated mice sera were diluted in blocking buffer and incubated O/N at 4°C.
The following steps were as described above. A scrambled peptide was used as a negative control. 
Surface Plasmon Resonance
Surface plasmon resonance (SPR) was performed using Biacore 3000 optical biosensor equipped with research-grade CM5 sensor chips (Biacore GE Healthcare), as previously described (41) . Experimental details are provided in Supplementary Materials and Methods.
Competition assay of UN1 mAb binding
The UN1 mAb (0.37 μg/mL) was pre-incubated O/N at 4°C with CsCl-purified phages (3x10 12 up to 3x10 8 phage particles/ml), or with synthetic peptides (0.04 μg/mL up to 400 μg/mL). The mixture was added to HPB-ALL cells (5x10 5 ) and incubated for 30 min at 4°C.
After washing, the cells were incubated for additional 30 min at 4°C with FITC-conjugated rabbit anti-mouse immunoglobulins F(ab')2, and analyzed with BD FACSCalibur cytometer.
Results were analyzed by CellQuest software (BD Biosciences, Erembodegem, Belgium)
.
Mice immunization
Five-six week old female Balb/c mice (Harlan, Udine, Italy) were immunized by intraperitoneal injection of CsCl-purified 2/165 phage particles, or wild type phage at weeks 0, 3, 6, 9, 12, 15, 18. The animals were bled at day 0 and 7-10 days after the 2nd, 4th and 6th
boost. Phages were injected as PBS suspension in CFA (Freund's complete adjuvant) at week 0 or IFA (Freund's incomplete adjuvant) at a concentration of 6x10 12 phage particles/mL.
Serum IgGs from mice immunized with 2/165 phage, or wild type phage, or not-immunized were purified by MAbTrap kit (GE Healthcare).
In vivo toxicity
Serum levels of inflammatory interleukin-1-β (IL1-β) were measured by ELISA (eBiosciences), according to the manufacturer's instructions. The hepatotoxicity marker glutathione (GSH) and lactate dehydrogenase (LDH) were assayed by a colorimetric assay (Promega), according to the manufacturer's instructions.
Immunoaffinity purification of antibodies
Immunoglobulins were purified by incubating mice sera at 1:10 dilution in multi-well plates coated with 5x10 12 /ml CsCl-purified phages. After extensive washing, the bound immunoglobulins were eluted with 0.1 M glycine-HCl buffer pH 2.7, 10 μg/ml BSA immediately neutralized with 2 M Tris-HCl pH 9.4, and concentrated using Microcon Ultracel YM-30 (Millipore, Bedford, MA, USA).
Immunohistochemistry
Surgical specimens were derived from breast and gastric cancer tissues of the patients hospitalized at the clinical surgery Federico II University of Naples. The informed consent to research activity was expressed by patients at the time of surgery for excision of neoplasia, analysed at the section of Pathological Anatomy (department of advanced biomedical sciences Federico II University of Naples). Immunohistochemical analysis was performed as previously described (6, 7) . Experimental details are provided in Supplementary Materials and Methods. 
Statistical analysis
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Results
UN1 mAb inhibited the tumor growth of UN1-positive leukemic T-cells in nude mice
Based on the evidence that the UN1 mAb specifically bound to UN1/CD43-positive neoplastic cells (6, 7) , we addressed the question of whether it could interfere the tumor growth in vivo. To this end, ten female six-weeks old NU/NU nude mice were tumor engrafted by subcutaneous injection of UN1-positive HPB-ALL cells into the lateral flank.
Then, mice were randomly divided in two groups (5 animals/group) and treated with the UN1 mAb or IgG 1 control (400 μg/mouse) by injection in the tail vein at day 1 and 7 after tumor 
UN1 mAb caused HPB-ALL cell lysis via antibody-dependent cell-mediated cytotoxicity
To understand the mechanism of UN1 mAb-inhibition of HPB-ALL tumor growth, we analysed the direct effect of the UN1 mAb on cell growth by incubating the HPB-ALL cells with the UN1 mAb (1 up to 25 μg/ml), or IgG 1 negative control. The UN1 mAb did not affect the proliferation rate, cell cycle, the number of viable and apoptotic cells as compared to untreated or IgG-treated cells (Fig. S1 A-D) . Further, we analysed whether the UN1 mAb could act via complement-mediated cell lysis. Cytotoxicity was assessed by incubating HPB-ALL cells with or without UN1 mAb, in presence or absence of the complement. W6/32 mAb and IgG were included as positive and negative controls, respectively. Differently from W6/32 mAb, the UN1 mAb did not affect cell lysis (Fig 1C) . 
Cultured primary NK cells from nine healthy donors were tested in a standard ADCC assay.
A significant antibody-mediated lysis of tumor cells (p = 0.0026) was observed in the UN1 mAb-opsonized samples as compared to not-opsonised controls, being the UN1-opsonized targets were killed more efficiently in seven out of nine donors (Fig. 1D) . Moreover, ADCC induced by UN1 mAb was slightly lower as compared to W6/32 mAb (mean 21.9% vs 24.4%), or OKT3 mAb (mean 21.9% vs 32.3%) (Fig. 1D) . The ability of UN1 mAb to induce ADCC was also supported by the analysis of lytic units within the same donor, which were calculated for the whole curve effector/target cells (E/T) ratio (Fig. 1E) . For the UN1, OKT3
and W6/32 mAbs the strenght of binding to HBP-ALL cells directly correlated with their ADCC potency (Fig. S2A) , which was likely due to the expression levels of cognate antigens on cell surface.
Identification of the UN1 mimotope by phage displayed RPL
Based on the UN1 mAb inhibition of UN1-positive tumor cells, we reasoned that the identification of the UN1/CD43 epitope recognized by the UN1 mAb could be useful for developing novel immunogens for cancer immunotherapy. To this end, we used the UN1 mAb to screen an f88-4/Cys5 phage displayed peptide library by two rounds of affinity selection. A phage enrichment was observed during the selection as the output/input phage ratio increased from 1.1x10 -6 after round I to 1.2x10 -2 after round II. After an immunoscreening step, 174 single phage clones were recovered and tested by ELISA for specific binding to the UN1 mAb and, among them, 153 clones were found to react with the UN1 mAb. OD values of positive phagotopes ranged between 4 -40 folds higher than wild type phage ( Fig. 2A) . Based on these results, 28 phage clones showing the strongest positive signal were selected for DNA sequencing, which yielded 11 different peptide mimotopes sequences (Table  1) . MUSCLE-based alignment analysis (http://www.ebi.ac.uk/Tools/msa/muscle/) showed a significant homology between the 11 peptides and the human protein CD43 (Fig. 2B) , which is the natural antigen recognized by UN1 mAb (4). Indeed, the homology region of the 11 amino acidic sequences of mimotopes falls in the extra-cellular domain of CD43 (amino acids 64 to 83), a region that undergoes highly O-linked glycosylation (4). Among the 11-selected clones, the phagotope 2/165 was chosen due to the strongest reactivity against UN1 mAb in ELISA (Table 1) .
Two peptides were synthesized corresponding to the insert of the 2/165 phagotope (W15 peptide: TPHTCKLLDECVPLW) and a longer synthetic peptide containing the W15 peptide sequence with additional amino acid residues flanking the insert of the phagotope 2/165 (G23 peptide: SFAATPHTCKLLDECVPLWPAEG). As negative control, a scrambled peptide was synthesized (TCLAPDVPEPLSHCWAGETFKLA). By surface plasmon resonance (SPR), we measured binding affinity of the peptides W15 and G23 to the UN1 mAb. Sensorgrams showed that G23 and W15 peptides exhibited similar affinities for the UN1 mAb (K D 155 nM and 142 nM, respectively) while the scrambled peptide failed to give the SPR signal (Fig. 2C) .
Phagotope 2/165 and UN1 peptide mimotopes competed the binding of UN1 mAb to tumor cells
Next, we determined whether the phage clone 2/165 and the peptides W15 and G23 mimic the structure of the UN1 epitope. To this end, we performed a competitive inhibition assay for the binding of the UN1 mAb to the HPB-ALL cells in presence or absence of the phagotope 2/165 or the peptide mimotopes. The binding of UN1 mAb to HPB-ALL cells was significantly reduced in presence of phage 2/165 (Fig. 3A, B) , G23 or W15 peptides (Fig. 3C,   D ) in a dose-related manner. This effect was not observed in presence of wild type phage or scrambled peptide (Fig. 3A-D) . Conversely, the phage 2/165 and the peptides G23 and W15 did not compete the binding of W6/32 mAb, an anti-human HLA class I antigen (Fig. S2B) .
As additional evidence of structural similarity to the UN1/CD43 epitope, the phage 2/165 and G23 competed the binding of UN1 mAb to UN1-positive breast and gastric cancer tissues, while the wild type phage and scrambled peptide did not (Fig. S3) . These results indicated that the phagotope 2/165 as well as the derived G23 and W15 peptides mimicked the conformation of the UN1/CD43 epitope.
Mice immunization with phagotope 2/165 elicited antibodies against the UN1/CD43 natural antigen
Filamentous phage can be used as immunogen as they elicit a strong antibody response in different animal systems (43, 44). Thus, we analysed the immunogenicity of the phagotope 2/165 in mice. Balb/c mice (5 animals/group) were immunized with the phage 2/165, or wild type phage, and the collected sera were analysed for reactivity against the wild type phage, G23 or a scrambled peptide as control (Fig. 4) . Both wild type phage-and 2/165 phagotopeimmunized mice appeared healthy and did not show any ill-effect. Moreover, both groups of immunized mice showed levels of serum inflammatory cytokine IL1-β, and hepatotoxicity marker GSH and LDH in the range of normality ( Table 2 ), indicating that phage immunization was not toxic.
As expected, both groups of immunized mice developed a strong and comparable antibody response against the wild type phage, while control serum from a non-immunized mouse showed no reactivity (Fig. 4A, B, left panels) . However, the phagotope 2/165-immunized mice sera showed a specific immune response against the UN1 mimotope G23 peptide (1:20,000 up to 1:100,000 antibody titer) (Fig. 4A, middle panel) , while they were unreactive against the scrambled peptide (Fig. 4A, right panel) . As negative control, the pre-immune and wild type-phage immunized mice sera did not show any detectable reactivity against the G23 (Fig. 4B, middle panel) , or scrambled peptide (Fig. 4B, right panel) . As further analysis of 2/165 phagotope-induced antibodies recognition of UN1 epitope, immunoglobulins were affinity-purified from sera of 2/165 phagotope immunized mice or pre-immune sera using the 2/165 phagotope or wild type phage as ligand. The immunoglobulins (Igs) eluted from 2/165 phagotope (2/165 Igs) reacted with the G23 peptide, whereas Igs eluted from wild type phage (wt Igs) did not (Fig. S4A) . Further, by flow cytometry we confirmed that the 2/165 Igs bound to the HPB-ALL cells (Fig. S4B) . On the basis of the reported reactivity of the UN1 mAb with tumor tissues (6, 7), we tested whether the 2/165 IgGs detected UN1-positive human breast and gastric cancer by immunohistochemistry. We found that 2/165 IgGs specifically reacted with breast and gastric cancer tissues with a pattern similar to the one observed with the UN1 mAb (Fig. 5) . Conversely, no reactivity against the cancer tissues was observed using the wt IgGs or pre-immune IgGs (Fig. 5) . The binding specificity of the 2/165 IgGs to UN1-positive cancer tissues was confirmed by competition assays. Indeed, the pre-incubation of 2/165 IgGs with the 2/165 phagotope or the UN1 mimotope G23 peptide inhibited the binding of 2/165 IgGs to UN1-positive tumor tissues, confirming the binding specificity of 2/165 IgGs to the UN1 epitope exposed on tumor cells (Fig. 6) .
Discussion
CD43 is a transmembrane sialoglycoprotein that is mostly expressed in haematopoietic cells, and tumor cells of non-haematopoietic origin. CD43 signalling activates cellular pathways leading to activation of NF-κB and AP1 transcription factors that up-regulate the expression of pro-survival and proliferation genes (45) . Deregulation of CD43 signalling can promote cancer phenotype (45) . We previously reported that specific CD43 glycoforms were recognized by the UN1 mAb and were highly expressed in lymphoblastoid T-cell lines and 4, 6, 7) . In particular, the expression of UN1-type CD43 in breast cancer correlated with the grade of malignancy, suggesting that the specific CD43 glycoforms could promote an altered proliferation signalling and cause cancer progression (6, 7) . Based on this evidence, the UN1 mAb was considered a suitable tool for cancer immunophenotyping.
The aim of this study was to evaluate the immunotherapeutic activity of the UN1 mAb based on the ability of this monoclonal antibody to target specifically the cancer cells expressing the UN1-type CD43 glycoforms. We observed that the passive transfer of the UN1 mAb inhibited the growth of UN1-positive HPB-ALL lymphoblastoid T-cells upon xenograft in mice, suggesting a possible use of this antibody for cancer immunotherapy. We excluded that tumor growth inhibition was due to direct cytostatic or cytotoxic activity of the UN1 mAb since the proliferation rate, cell cycle, and viability of HPB-ALL cells were unaffected by the UN1 mAb in cell culture. Conversely, the UN1 mAb induced the in vitro lysis of HPB-ALL cells via antibody-dependent NK-mediated cytotoxicity. Based on these findings, the UN1 mAb behaved similarly to the antibodies that are currently used in cancer therapy against specifically or differentially expressed tumor antigens, such as anti-CD20 (rituximab), anti Her-2/neu (trastuzumab), and anti-EGFR (cetuximab) (46) . It is worth mentioning that such validated anti-cancer therapeutic mAbs exhibited multiple effector mechanisms for their in vivo anti-tumour activity (46) . Even though additional mechanisms of UN1 mAb action require further investigation, such as receptor down-modulation, ligand blockade or antibodydependent cellular phagocytosis (ADCP), the in vitro analysis performed in this study indicates that ADCC could be a major mechanism of in vivo anti-tumor activity.
We also explored the possibility to generate a mimotope of the UN1/CD43 epitope to be used as immunogen for eliciting highly specific Abs against the UN1-positive tumor tissues.
By screening an f88-4/Cys5 phage displayed peptide library with the UN1 mAb, we identified and characterized eleven peptide binders of the UN1 mAb. Among the selected phage clones, the peptide insert of phagotope 2/165 was a true UN1/CD43 epitope mimic because it was specifically recognized by the UN1 mAb and inhibited the binding of the UN1 mAb to the UN1/CD43 natural antigen, meeting the previously established guidelines for specificity and mimicry testing (47) . Several studies have indicated that cysteine-constrained phage displayed peptides are endowed with a stabilized conformation that allows the isolation of cyclic peptides with a higher affinity toward a bait as compared to non-constrained, linear peptides (48) . Moreover, cysteine-constrained phage-derived peptides have been shown to bind the cognate ligand outside of the phage coat protein (38) For vaccine purpose, glycosylated antigens are difficult to synthesize and purify in large quantities, and usually induce a poor immune response with short-lived IgM-type antibodies.
Novel strategies of vaccine production are required to overcome these major limitations (17) .
Phage mimotopes of cancer antigens (18, (21) (22) (23) Serial sections of surgical specimens derived from breast and gastric cancer tissues were stained with 2/165 IgGs, pre-incubated overnight at 4°C with the indicated phage (2.5x10 13 phage particles/mL) or peptide (500 μg/mL), according to peroxidase-antiperoxidase method.
Original magnification x200.
